Page last updated: 2024-09-04

dx 8951 and Adenocarcinoma

dx 8951 has been researched along with Adenocarcinoma in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Coyle, J; DeJager, R; Hoff, PM; Pazdur, R; Rowinsky, EK; Royce, ME; Saltz, LB1
Abou-Alfa, GK; Becerra, CR; De Jager, R; Eckhardt, SG; Feit, K; Kelsen, DP; O'Reilly, EM; Patt, YZ; Rowinsky, EK; Schwartz, GK; Sharma, S; Siegel, E1
Ajani, JA; Baez, L; Becerra, CR; Cohn, A; De Jager, R; Feit, K; Kamida, M; Major, P; Silva, A; Takimoto, C1

Trials

3 trial(s) available for dx 8951 and Adenocarcinoma

ArticleYear
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum.
    Investigational new drugs, 2004, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Female; Humans; Male; Middle Aged; Rectal Neoplasms

2004
A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers.
    American journal of clinical oncology, 2005, Volume: 28, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Area Under Curve; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Drug Administration Schedule; Female; Gallbladder Neoplasms; Half-Life; Humans; Male; Middle Aged; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome

2005
A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer.
    Investigational new drugs, 2005, Volume: 23, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Stomach Neoplasms; Treatment Outcome

2005